Misframed proteins and neurodegeneration: A novel view on Alzheimer's and Parkinson's diseases

Neurodegenerative Diseases

Volumn 7, Issue 1-3, 2010, Pages 76-79

  Dennissen, F J A ^a   Kholod, N ^a   Steinbusch, H W M ^a   Van Leeuwen, F W ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Amyloid precursor protein; Molecular misreading; Protein quality control; Ubiquitin; Ubiquitin proteasome system

Indexed keywords

AMYLOID PRECURSOR PROTEIN; PROTEASOME; UBIQUITIN; UBIQUITIN B; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN CORTEX; CONFERENCE PAPER; CORPUS STRIATUM; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; NERVE DEGENERATION; PARKINSON DISEASE; PRIORITY JOURNAL;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; HUMANS; NERVE DEGENERATION; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 76749094093     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000285510     Document Type: Conference Paper

References (22)

1. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA: Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216-223.
2. Schnabel J: Alzheimer's theory makes a splash. Nature 2009; 459: 310.
3. Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009; 457: 981-989.
4. van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, Sluijs JA, Koycu S, Ramdjielal RD, Salehi A, Martens GJ, Grosveld FG, Peter J, Burbach H, Hol EM: Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 1998; 279: 242-247.
5. Gerez L, de Haan A, Hol EM, Fischer DF, van Leeuwen FW, van Steeg H, Benne R: Molecular misreading: the frequency of dinucleotide deletions in neuronal mRNAs for betaamyloid precursor protein and ubiquitin B. Neurobiol Aging 2005; 26: 145-155.
6. Fischer DF, De Vos RA, Van Dijk R, De Vrij FM, Proper EA, Sonnemans MA, Verhage MC, Sluijs JA, Hobo B, Zouambia M, Steur EN, Kamphorst W, Hol EM, Van Leeuwen FW: Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain. FASEB J 2003; 17: 2014-2024.
7. Schwartz AL, Ciechanover A: Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol 2009; 49: 73-96.
8. Tan Z, Sun X, Hou FS, Oh HW, Hilgenberg LG, Hol EM, van Leeuwen FW, Smith MA, O'Dowd DK, Schreiber SS: Mutant ubiquitin found in Alzheimer's disease causes neuritic beading of mitochondria in association with neuronal degeneration. Cell Death Differ 2007; 14: 1721-1732.
9. van Tijn P, de Vrij FM, Schuurman KG, Dantuma NP, Fischer DF, van Leeuwen FW, Hol EM: Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease. J Cell Sci 2007; 120: 1615-1623.
10. Lindsten K, de Vrij FM, Verhoef LG, Fischer DF, van Leeuwen FW, Hol EM, Masucci MG, Dantuma NP: Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J Cell Biol 2002; 157: 417-427
11. Park Y, Yoon SK, Yoon JB: The HECT domain of TRIP12 ubiquitinates substrates of the ubiquitin fusion degradation pathway. J Biol Chem 2009; 284: 1540-1549.
12. Verhoef LG, Heinen C, Selivanova A, Halff EF, Salomons FA, Dantuma NP: Minimal length requirement for proteasomal degradation of ubiquitin-dependent substrates. FASEB J 2009; 23: 123-133.
13. Paine S, Bedford L, Thorpe JR, Mayer RJ, Cavey JR, Bajaj N, Sheppard PW, Lowe J, Layfield R: Immunoreactivity to Lys63- linked polyubiquitin is a feature of neurodegeneration. Neurosci Lett 2009; 460: 205-208.
14. Shabek N, Herman-Bachinsky Y, Ciechanover A: Ubiquitin degradation with its substrate, or as a monomer in a ubiquitination- independent mode, provides clues to proteasome regulation. Proc Natl Acad Sci USA 2009; 106: 11907-11912.
15. Kim HT, Kim KP, Uchiki T, Gygi SP, Goldberg AL: S5a promotes protein degradation by blocking synthesis of nondegradable forked ubiquitin chains. EMBO J 2009; 28: 1867-1877.
16. de Pril R, Fischer DF, Maat-Schieman ML, Hobo B, de Vos RA, Brunt ER, Hol EM, Roos RA, van Leeuwen FW: Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. Hum Mol Genet 2004; 13: 1803-1813.
17. van Leeuwen FW, van Tijn P, Sonnemans MA, Hobo B, Mann DM, Van Broeckhoven C, Kumar-Singh S, Cras P, Leuba G, Savioz A, Maat-Schieman ML, Yamaguchi H, Kros JM, Kamphorst W, Hol EM, de Vos RA, Fischer DF: Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies. Neurology 2006; 66: S86-S92.
18. Fischer DF, van Dijk R, van Tijn P, Hobo B, Verhage MC, van der Schors RC, Li KW, van Minnen J, Hol EM, van Leeuwen FW: Longterm proteasome dysfunction in the mouse brain by expression of aberrant ubiquitin. Neurobiol Aging 2009; 30: 847-863.
19. Pawlik M, Otero DA, Park M, Fischer WH, Levy E, Saitoh T: Proteins that bind to the RERMS region of beta amyloid precursor protein. Biochem Biophys Res Commun 2007; 355: 907-912.
20. Hol EM, van Dijk R, Gerez L, Sluijs JA, Hobo B, Tonk MT, de Haan A, Kamphorst W, Fischer DF, Benne R, van Leeuwen FW: Frameshifted beta-amyloid precursor protein (APP+1) is a secretory protein, and the level of APP+1 in cerebrospinal fluid is linked to Alzheimer pathology. J Biol Chem 2003; 278: 39637-39643.
21. van Dijk R, Fischer DF, Sluijs JA, Sonnemans MA, Hobo B, Mercken L, Mann DM, Hol EM, van Leeuwen FW: Frame-shifted amyloid precursor protein found in Alzheimer's disease and Down's syndrome increases levels of secreted amyloid beta40. J Neurochem 2004; 90: 712-723.
22. Fischer DF, Hol EM, Hobo B, van Leeuwen FW: Alzheimer-associated APP+1 transgenic mice: frameshift beta-amyloid precursor protein is secreted in cerebrospinal fluid without inducing neuropathology. Neurobiol Aging 2006; 27: 1445-1450.